Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Kidney Cancer treatment details. Immunotherapy. Beth Israel Deaconess Medical Center, Boston, MA, United States

Survival: 13.0 months
Toxicity Grade: 4
Treatments: Immunotherapy
Country: United States
City/State/Province: Boston, MA
Hospital: Beth Israel Deaconess Medical Center
Journal: Link
Date: 1/2005

Patients: This Phase III study involved a total of 192 patients with metastatic renal cell carcinoma. Patients were divided into two groups of 96 patients each. Each group was administered a different therapy.

Treatment: For Group A, the treatment consisted of high-dose interleukin-2 (IL-2). For Group B, the treatment consisted of subcutaneous IL-2 plus interferon.

Toxicities: Grade 3 and 4 toxicities for group B iincluded: constitutional, hypotension gastrointestinal, hematologic, neurologic, cardiac, pulmonary, renal/electrolytes, psychiatric, hepatic, and infection.

Results: Median survival was 13 months for Group B.

Support: Several of the study's authors have acted as consultants, performed contract work for, or received more than $2,000/year from Chiron or Schering. Chiron markets IL-2. Schering markets interferon.

Correspondence: David F. McDermott, MD

E-mail to a Friend Email Physician More Information